Mission Bio has launched the “first and only” platform capable of sequencing DNA and protein in a single cell, in order to identify more accurate cancer targets for precision medicine.
The company says that the single-cell multi-omic platform, dubbed Tapestri Platform, will enable key insights to “drive the development of more impactful cancer therapies”.
The technology is the first-of-its-kind in terms of detecting DNA and protein changes simultaneously from the same cell — a capability necessary for the development of impactful precision therapies.
The news comes as only 3% of cancer drugs tested in clinical trials between 2000 and 2015 have been approved to treat patients, and even those aimed at specific biomarkers like DNA mutations aren’t effective in every patient with that mutation, resulting in high rates of relapse.
“To better confront cancer and develop dynamic solutions that mirror the disease’s evolution, we require a more profound insight into every component that drives disease,” explained Nigel Beard, senior vice president, research & development at Mission Bio.
He continued, “These new capabilities double the size of the market for our Tapestri Platform’s applications, and now we provide double the insight into disease drivers so our customers can accelerate cures.”
The multi-omics market is projected to reach $5 billion by 2025, and Mission Bio have put themselves one step ahead of the game, as the platform is now the first and only single-cell multi-omic platform to simultaneously detect single nucleotide variants (SNVs), copy number variants (CNVs) and proteins from the same cell.
